Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (4 Doses) Delivered by the Respimat® Inhaler in Patients With Asthma

NCT00467740 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00467740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00467740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (4 Doses) Delivered by the Respimat® Inhaler in Patients With Asthma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
Not reported
Enrollment
296 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

asthma